[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477983":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":32,"studyPopulation":33,"armGroups":34,"interventions":44,"overallOfficials":58,"centralContacts":63,"locations":69,"responsibleParty":94,"collaborators":97,"id":100,"slug":28,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":28,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":107,"minAge":28,"maxAge":28,"enrollmentInfo":108,"targetDuration":28,"studyType":111,"phases":28,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":72,"whyStopped":28,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Consorci Sanitari de Terrassa","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":28},[9],{"measure":10,"description":11,"timeFrame":12},"Hospital Admissions.","Rate of Hospitalization among COVID 19 infections","from march 2020.",[14,18,21,25],{"measure":15,"description":16,"timeFrame":17},"Survival","Survival among COVID1 hospitalized cases.","from march 2020",{"measure":19,"description":20,"timeFrame":17},"Symptomatic infection","Patients suffering a symptomatic COVID19 infection within a determinate age group",{"measure":22,"description":23,"timeFrame":24},"Postcovid syndrome","Patients developing postcovid syndrome after COVID19 infection","from april 2020",{"measure":26,"description":27,"timeFrame":24},"Thrombosis","Patients developing thrombosis (with particular assessment of stroke, cardiac infarction, retinal vessels and pulmonary embolism)",null,{"allocation":28,"interventionModel":28,"interventionModelDescription":28,"primaryPurpose":28,"observationalModel":30,"timePerspective":31,"maskingInfo":28},"CASE_CONTROL","RETROSPECTIVE","BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection.\n\nOBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19.\n\nMETHODS. Describe the rate of hospitalization, ICU, survival, postcovid syndrome and thrombosis among COVID 19 cases having antihistamines and amantadine as chronic treatments.\n\nThe rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.","Population assigned to the Public and free Access Terrassa Health Consortium",[35,41],{"label":36,"type":28,"description":37,"interventionNames":38},"Patients with chronic treatment with antihistamines or amantadine","The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups.",[39,40],"Drug: Antihistamine","Drug: Amantadine",{"label":42,"type":28,"description":43,"interventionNames":28},"Other population of the THC","The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups.",[45,52],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"DRUG","Antihistamine","Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines",[36],[51],"Antihistamine as crhonic treatment and COVID19 infection.",{"type":46,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Amantadine","Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine",[36],[57],"Amantadine as chronic treatment and COVID19 infection.",[59],{"name":60,"affiliation":61,"role":62},"Anna Puigdellívol, PhD","Terrassa Health Consortium","PRINCIPAL_INVESTIGATOR",[64],{"name":65,"role":66,"phone":67,"phoneExt":28,"email":68},"Anna Puigdellivol, Ph.D","CONTACT","34-93-5884555","apuigdellivol@cst.cat",[70,87],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Hospital de Terrassa","RECRUITING","Terrassa","Barcelona","08227","Spain","ES",{"type":79,"coordinates":80},"Point",[81,82],2.01667,41.56667,{"lat":82,"lon":81},[85],{"name":86,"role":66,"phone":67,"phoneExt":28,"email":68},"Anna Puigdellívol-Sánchez, Ph.D.",{"facility":88,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":89,"geoPoint":91,"contacts":92},"Hospital of Terrassa",{"type":79,"coordinates":90},[81,82],{"lat":82,"lon":81},[93],{"name":60,"role":66,"phone":28,"phoneExt":28,"email":28},{"type":62,"investigatorFullName":95,"investigatorTitle":96,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Anna Puigdellívol-Sánchez","Principal Investigator",[98],{"name":99,"class":6},"Institut Català de la Salut","100477983",false,"NCT05504057","Antihistamines, Amantadine and Evolution of COVID-19","Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection","Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine -\n\nExclusion Criteria: None\n\n\\-",true,"ALL",{"count":109,"type":110},140660,"ESTIMATED","OBSERVATIONAL","The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.",[114],"COVID-19",[116,117,118,119],"antihistamines","amantadine","hospital admissions","survival","2026-03-30",{"date":122,"type":123},"2026-04-03","ACTUAL",{"date":125,"type":123},"2020-03-01",{"date":127,"type":110},"2028-02-24",{"name":5,"class":6},2]